Literature DB >> 2206998

Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease.

H F Tien1, C H Wang, Y C Chen, M C Shen, H S Wu, F Y Lee, S M Chuang, C H Liu.   

Abstract

Among 77 unselected patients with chronic myelogenous leukaemia (CML), 70 had Philadelphia chromosome (Ph1) in blood cells. Extra chromosomal abnormalities were noted in 4%, 55% and 78% of Ph1-positive patients in chronic phase, accelerated phase and acute blast crisis, respectively. Rearrangement of the bcr was detected in 46 of 47 Ph1-positive patients studied and also in three of five Ph1-negative ones. The locations of the breakpoints were mapped to one of four zones of the bcr in 45 patients. The median duration from diagnosis of CML to onset of acute blast crisis was not significantly different between the two groups of patients with breakpoints in the 5' portion (34 months), and in the 3' portion (39 months) of the bcr. In addition, the locations of the breakpoints within the bcr did not change as the disease progressed in the six patients who had DNA analysed both in the chronic phase and subsequently in transformation. In one of them, an additional aberrant band which was not present in the beginning of the acute phase was detected in blood cells taken 2 months later. It is suggested from the studies that transformation of CML may not be related to alterations within the bcr.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206998     DOI: 10.1111/j.1365-2141.1990.tb07784.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

Review 1.  Myelodysplastic syndromes.

Authors:  I M Hann
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

2.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.